Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

treatment for a total of 48 weeks.

About RG7227/ ITMN-191

RG7227/ ITMN-191 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced multi-log10 reductions in HCV levels in chronic HCV patients, when administered for 14 days as monotherapy. When RG7227/ ITMN-191 is combined with PEGASYS and COPEGUS, or the NS5B polymerase inhibitor RG7128, it reduced viral loads below the limit of detection in a majority of study-treated patients. RG7227/ ITMN-191 was safe and well tolerated in these studies.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic HCV who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic HCV in patients coinfected with HCV and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in HCV, with major studies initiated to advance treatment for HCV patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and p
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... device is being prepped to enter the battle ... of certain diseases in remote areas, thanks in ... investigations aboard the International Space Station on the ... concept of capillary flow to diagnose infectious diseases ... Ph.D., a researcher at Northwestern University in Evanston, ...
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... of death in Lake County , ... Evanston, IL (Vocus) March 12, ... a $1 million commitment to the Lake County Health Department and Community ... to addressing the steadily growing problem of diabetes in the county. , ...
... National Center for Creative Aging (NCCA) will feature certification on ... of the "NCCA-MetLife Foundation Creativity Matters: Health, Wellness, and ... March 30, 31, April 1 . Anne ... at the University of Wisconsin and Founder and ...
... Well-known for its preventive care initiatives, state,s largest ... American Lung Association to provide medical professionals the ... Live Well programCHARLESTON, W.Va., March 12 The ... UniCare Health Plan of West Virginia, Inc. (UniCare) ...
... finding and help fight obesity , , THURSDAY, March 12 (HealthDay ... may keep children more active and help combat the continued ... For every park found within a half-mile of home, a ... odds of taking part in leisure walking increased by 60 ...
... What,s Safe to Eat and Who,s Most At RiskLANSING, ... food safety legislation under debate in the U.S. Senate ... that Americans are more concerned than ever when it ... alarmingly unaware of the long-term side effects of Salmonella, ...
... the forthcoming 24th Annual EAU Congress in Stockholm (SE), which ... organizing three Meet the Expert sessions. These are press meetings ... in the Press Centre of the congress venue. In these ... the experts their questions practically one-on-one. , The first session,s ...
Cached Medicine News:Health News:NorthShore University HealthSystem Launches Diabetes Outreach Program for Lake County's Medically Underserved 2Health News:NorthShore University HealthSystem Launches Diabetes Outreach Program for Lake County's Medically Underserved 3Health News:NorthShore University HealthSystem Launches Diabetes Outreach Program for Lake County's Medically Underserved 4Health News:National Center for Creative Aging Features Timeslips in 'Creativity Matters' Symposium on Health, Wellness, and the Arts 2Health News:UniCare Health Plan of West Virginia Providing Assistance for Asthma Education Training 2Health News:UniCare Health Plan of West Virginia Providing Assistance for Asthma Education Training 3Health News:Kids Who Live Near Green Spaces Seem to Walk More 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 2Health News:Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning 3Health News:Meet the expert sessions at the 24th Annual EAU Congress 2
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BURLINGTON, Mass., Dec. 12, 2011 /PRNewswire-iReach/ -- ... Financial. Tom joined Ametros as executive vice president in ... in the workers, compensation managed care industry. He served ... Medical, vice president of national occupational health for Kaiser ...
... Ontario, Dec. 12, 2011  Valeant Pharmaceuticals International, Inc. ... at a special meeting of shareholders of Afexa ... today in Calgary, Alberta, the shareholders of Afexa ... subsidiary, 1625907 Alberta Ltd. (the " Offeror ") ...
Cached Medicine Technology:Ametros Financial Names Thomas Ash as CEO 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 3
... The optimal combination of performance ... New 4x5 mL swinging bucket rotor. ... 0.2 ml to 8.3 ml, with ... drive, very quiet operation, rotor imbalance ...
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... power for small-volume samples. With the ability ... removing chylomicrons (fat particles in lipemic samples), ... lipemic clarification. Lipemic samples can be cleaned ... sendouts. The easy-to-operate tabletop centrifuge: Reaches ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: